Literature DB >> 33046553

MeCP2 Levels Regulate the 3D Structure of Heterochromatic Foci in Mouse Neurons.

Aya Ito-Ishida1,2,3,4, Steven A Baker5,2,3, Roy V Sillitoe6,7,8,2,3, Yaling Sun5,2,3, Jian Zhou5,2,3, Yukiteru Ono9, Junichi Iwakiri9, Michisuke Yuzaki4, Huda Y Zoghbi1,6,10,11,2,3.   

Abstract

Methyl-CpG binding protein 2 (MeCP2) is a nuclear protein critical for normal brain function, and both depletion and overexpression of MeCP2 lead to severe neurodevelopmental disease, Rett syndrome (RTT) and MECP2 multiplication disorder, respectively. However, the molecular mechanism by which abnormal MeCP2 dosage causes neuronal dysfunction remains unclear. As MeCP2 expression is nearly equivalent to that of core histones and because it binds DNA throughout the genome, one possible function of MeCP2 is to regulate the 3D structure of chromatin. Here, to examine whether and how MeCP2 levels impact chromatin structure, we used high-resolution confocal and electron microscopy and examined heterochromatic foci of neurons in mice. Using models of RTT and MECP2 triplication syndrome, we found that the heterochromatin structure was significantly affected by the alteration in MeCP2 levels. Analysis of mice expressing either MeCP2-R270X or MeCP2-G273X, which have nonsense mutations in the upstream and downstream regions of the AT-hook 2 domain, respectively, showed that the magnitude of heterochromatin changes was tightly correlated with the phenotypic severity. Postnatal alteration in MeCP2 levels also induced significant changes in the heterochromatin structure, which underscored importance of correct MeCP2 dosage in mature neurons. Finally, functional analysis of MeCP2-overexpressing mice showed that the behavioral and transcriptomic alterations in these mice correlated significantly with the MeCP2 levels and occurred in parallel with the heterochromatin changes. Taken together, our findings demonstrate the essential role of MeCP2 in regulating the 3D structure of neuronal chromatin, which may serve as a potential mechanism that drives pathogenesis of MeCP2-related disorders.SIGNIFICANCE STATEMENT Neuronal function is critically dependent on methyl-CpG binding protein 2 (MeCP2), a nuclear protein abundantly expressed in neurons. The importance of MeCP2 is underscored by the severe childhood neurologic disorders, Rett syndrome (RTT) and MECP2 multiplication disorders, which are caused by depletion and overabundance of MeCP2, respectively. To clarify the molecular function of MeCP2 and to understand the pathogenesis of MECP2-related disorders, we performed detailed structural analyses of neuronal nuclei by using mouse models and high-resolution microscopy. We show that the level of MeCP2 critically regulates 3D structure of heterochromatic foci, and this is mediated in part by the AT-hook 2 domain of MeCP2. Our results demonstrate that one primary function of MeCP2 is to regulate chromatin structure.
Copyright © 2020 the authors.

Entities:  

Keywords:  MeCP2; Rett syndrome; chromatin; imaging; neuron

Mesh:

Substances:

Year:  2020        PMID: 33046553      PMCID: PMC7643291          DOI: 10.1523/JNEUROSCI.1281-19.2020

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

1.  REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis.

Authors:  Nurit Ballas; Christopher Grunseich; Diane D Lu; Joan C Speh; Gail Mandel
Journal:  Cell       Date:  2005-05-20       Impact factor: 41.582

2.  Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin.

Authors:  Tatiana Nikitina; Xi Shi; Rajarshi P Ghosh; Rachel A Horowitz-Scherer; Jeffrey C Hansen; Christopher L Woodcock
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

3.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.

Authors:  X Nan; H H Ng; C A Johnson; C D Laherty; B M Turner; R N Eisenman; A Bird
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

4.  MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin.

Authors:  X Nan; F J Campoy; A Bird
Journal:  Cell       Date:  1997-02-21       Impact factor: 41.582

5.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.

Authors:  J Guy; B Hendrich; M Holmes; J E Martin; A Bird
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

6.  Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies.

Authors:  Rodney C Samaco; Christopher M McGraw; Christopher S Ward; Yaling Sun; Jeffrey L Neul; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2012-10-01       Impact factor: 6.150

7.  Different central nervous system cell types display distinct and nonrandom arrangements of satellite DNA sequences.

Authors:  L Manuelidis
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  A high-resolution imaging approach to investigate chromatin architecture in complex tissues.

Authors:  Michael W Linhoff; Saurabh K Garg; Gail Mandel
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

9.  MeCP2 regulates gene expression through recognition of H3K27me3.

Authors:  Wooje Lee; Jeeho Kim; Jung-Mi Yun; Takbum Ohn; Qizhi Gong
Journal:  Nat Commun       Date:  2020-06-19       Impact factor: 14.919

10.  An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders.

Authors:  Steven Andrew Baker; Lin Chen; Angela Dawn Wilkins; Peng Yu; Olivier Lichtarge; Huda Yahya Zoghbi
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

View more
  5 in total

1.  Expression, Purification, Characterization and Cellular Uptake of MeCP2 Variants.

Authors:  Alexander V Beribisky; Hannes Steinkellner; Sofia Geislberger; Anna Huber; Victoria Sarne; John Christodoulou; Franco Laccone
Journal:  Protein J       Date:  2022-05-12       Impact factor: 4.000

2.  Deleting Mecp2 from the cerebellum rather than its neuronal subtypes causes a delay in motor learning in mice.

Authors:  Nathan P Achilly; Ling-Jie He; Olivia A Kim; Shogo Ohmae; Gregory J Wojaczynski; Tao Lin; Roy V Sillitoe; Javier F Medina; Huda Y Zoghbi
Journal:  Elife       Date:  2021-01-26       Impact factor: 8.140

Review 3.  The Molecular Functions of MeCP2 in Rett Syndrome Pathology.

Authors:  Osman Sharifi; Dag H Yasui
Journal:  Front Genet       Date:  2021-04-23       Impact factor: 4.599

4.  MeCP2-induced heterochromatin organization is driven by oligomerization-based liquid-liquid phase separation and restricted by DNA methylation.

Authors:  Hui Zhang; Hector Romero; Annika Schmidt; Katalina Gagova; Weihua Qin; Bianca Bertulat; Anne Lehmkuhl; Manuela Milden; Malte Eck; Tobias Meckel; Heinrich Leonhardt; M Cristina Cardoso
Journal:  Nucleus       Date:  2022-12       Impact factor: 4.197

5.  MeCP2 inhibits ischemic neuronal injury by enhancing methylation of the FOXO3a promoter to repress the SPRY2-ZEB1 axis.

Authors:  Lei Meng; Bin Feng; Liming Luan; Zhihao Fang; Guangyu Zhao
Journal:  Exp Mol Med       Date:  2022-08-01       Impact factor: 12.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.